SPECIFIC PATTERN OF F-2-FLUORO-2-DEOXY-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY IN DIFFERENTIAL DIAGNOSIS OF ALZHEIMER DISEASE: CASE REPORT

B. Radović ,
B. Radović

The Faculty of Medical Science, University of Priština - Kosovska Mitrovica, Mitrovica, Kosovo

Centre for Nuclear Medicine Clinical Centre of Serbia, Belgrade, Serbia

L. Brajkovic ,
L. Brajkovic

Centre for Nuclear Medicine Clinical Centre of Serbia, Belgrade, Serbia

S. Nikolic
S. Nikolic

The Faculty of Medical Science, University of Priština - Kosovska Mitrovica, Mitrovica, Kosovo

Published: 01.01.2019.

Volume 47, Issue 1 (2019)

pp. 39-43;

https://doi.org/10.70949/pramed201901422R

Abstract

Introduction: Dementia is a clinical diagnosis based on deficits of intellectual function, usually memory. Primarily neurodegenerative diseases are characterized by progressive neuronal damages and its synapsis. Early-onset Alzheimer disease 18 occurs in someone younger than 65. FDG-PET/CTis a quantitative tomographic technique also calleda biomarker of neuronal activity.

Case outline: A female of 54, mother, 12 years of education, an accountant, was sent to FDG-PET/CT brain scan because of loss of memory, social withdrawal, apathy, behavior changes, troubles with paying bills, speaking difficulties with no structural imaging abnormalities. PET scan reviled glucose hypometabolism in parietal lobes, left posterior cingulum, parietotemporal regions, the left parietooccipital region, left insula and temporal lobes. A male of 43, father, army corporal, 12 years of education, was sent to metabolic hybrid imaging because suspected dementia. He expressed progressive behavior decline, in a year time. The patient wasn't cooperative, could not concentrate and confabulated a lot. Forgetfulness, decline in voluntary dynamics and apathy dominated the clinical presentation. Structural imaging showed supratentorial, right precentral gyri solitary lesion and cortical bilateral hypocampal atrophy. FDG scan reviled distinctively diminished glucose metabolism posteriorly in parietal and temporal lobes, both posterior cingulum. SPM analysis confirmed the visually observed pattern of hypometabolism in both patients.


Conclusion: Depression is an important consideration in the differential diagnosis of AD. Early detection of AD through molecular imaging techniques will assist the choice of medications to slow the progression of the disease and optimize patient care.

Keywords

References

1.
DSM-5 Diagnostic Criteria for Major Depressive Disorder.
2.
WHO Mental Health Report.
3.
Mosconi L, Tsui WH, Herholz K. Multicentre standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. Vol. 49, J Nucl Med. p. 390–8.
4.
Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS. Fluorodeoxyglucose-Positron Emission Tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. Vol. 12, BMC Neurol. p. 9–41.
5.
Ishii K. PET Approaches for Diagnosis of Dementia. Vol. 35, Am J Neuroradiol. p. 2030–8.
6.
Perani D, Cerami C, Caminiti SP. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Vol. 43, Eur J Nucl Med Mol Imaging. p. 499–508.
7.
Herholz K. FDG PET and differential diagnosis of dementia. Vol. 9, Alzheimer Dis Assoc Disord. p. 9–16.
8.
Ishii K. PET Approaches for Diagnosis of Dementia. Vol. 35, Am J Neuroradiol. p. 2030–8.
9.
Boellaard R, Delgado-Bolton R, Oyen WJG. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Vol. 42, Eur J Nucl Med Mol Imaging. p. 328–54.
10.
Varrone A, Asenbaum S, Borght TV. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Vol. 36, Eur J Nucl Med Mol Imaging. p. 2103–10.
11.
Asenbaum S. Guideline for the use of FDG PET in Neurology and Psychiatry. Austrian Society of Nuclear Medicine.
12.
Kuwert T, Bartenstein P, Grünwald F. Clinical value of positron emission tomography in neuromedicine. Vol. 69, Position paper on results of an interdisciplinary consensus conference. Nervenarzt. p. 1045–60.
13.
Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Vol. 22, Sem Nucl Med. p. 233–46.
14.
Coleman RE. Positron Emission Tomography Diagnosis of Alzheimer’s Disease. Vol. 2, PET Clin. p. 25–34.
15.
Anchisi D, Borroni B, Franceschi M. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Vol. 62, Arch Neurol. p. 1728–33.
16.
Perani D, Della Rosa PA, Cerami C. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Vol. 6, Neuroimage Clin. p. 445–54.
17.
Yakushev I, Hammers A, Fellgiebel A. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Vol. 44, Neuroimage. p. 43–50.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by